| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ROS; MCF3; c-ros-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human ROS1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4篇关于ROS1抗体的参考文献及其摘要概括：
---
1. **文献名称**: *ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas*
**作者**: Rimkunas VM 等
**摘要**: 该研究开发了一种特异性ROS1抗体(D4D6克隆)，用于免疫组化(IHC)检测非小细胞肺癌(NSCLC)中的ROS1融合蛋白，并通过FISH验证其准确性，证明其在临床筛查中的实用性和可靠性。
---
2. **文献名称**: *Comparative Analyses of ROS1 Antibodies in NSCLC Reveal Differential Sensitivity and Diagnostic Applications*
**作者**: Shan L 等
**摘要**: 通过对比多种ROS1抗体(如D4D6、SP3B1克隆)在NSCLC组织中的表现，评估了不同抗体检测ROS1融合的敏感性和特异性，为临床选择抗体提供依据。
---
3. **文献名称**: *Antibody-Drug Conjugates Targeting ROS1 Fusion Proteins in Advanced Cancers*
**作者**: Drilon A 等
**摘要**: 研究报道了一种靶向ROS1的抗体药物偶联物(ADC)，通过特异性抗体结合ROS1阳性肿瘤细胞并递送细胞毒性药物，在临床前模型中显示出抗肿瘤活性。
---
4. **文献名称**: *ROS1 Testing in Lung Cancer: Review of Immunohistochemistry and Molecular Approaches*
**作者**: Facchinetti F, Tiseo M
**摘要**: 综述总结了ROS1检测方法，重点讨论了IHC抗体的应用场景及其局限性，强调结合FISH或NGS验证以提高诊断准确性。
---
注：以上文献为领域内代表性研究，如需具体发表年份或期刊信息，可进一步补充检索PubMed或Web of Science数据库。
ROS1 (c-ros oncogene 1) antibodies are critical tools in cancer research and diagnostics, particularly in identifying ROS1 rearrangements associated with oncogenesis. Discovered in 1986. ROS1 encodes a receptor tyrosine kinase (RTK) involved in cell differentiation, proliferation, and survival. While normally silent in most adult tissues, chromosomal rearrangements (e.g., CD74-ROS1 fusion) lead to constitutive kinase activation, driving tumor growth in cancers like non-small cell lung cancer (NSCLC), glioblastoma, and cholangiocarcinoma.
ROS1 antibodies are designed to detect either the ROS1 protein or specific fusion variants. In clinical practice, immunohistochemistry (IHC) using ROS1 antibodies serves as a cost-effective screening method to identify patients eligible for targeted therapies like crizotinib or entrectinib. These antibodies must exhibit high specificity to minimize cross-reactivity with structurally similar kinases like ALK or MET. Companion diagnostic assays using validated ROS1 antibodies are essential for guiding precision oncology decisions.
Research-grade ROS1 antibodies also facilitate mechanistic studies of ROS1 signaling pathways and drug resistance mechanisms. Challenges remain in optimizing antibody sensitivity for low-abundance fusion proteins and standardizing detection protocols across laboratories. As ROS1-targeted therapies expand, the development of next-generation ROS1 antibodies continues to play a pivotal role in advancing both diagnostic accuracy and therapeutic strategies for ROS1-driven cancers.
×
